NASDAQ:PIRS

Pieris Pharmaceuticals Stock Forecast, Price & News

$3.59
+0.11 (+3.16 %)
(As of 06/14/2021 02:22 PM ET)
Add
Compare
Today's Range
$3.44
$3.64
50-Day Range
$1.76
$3.81
52-Week Range
$1.70
$5.09
Volume48,736 shs
Average Volume27.74 million shs
Market Capitalization$227.25 million
P/E RatioN/A
Dividend YieldN/A
Beta1.17
30 days | 90 days | 365 days | Advanced Chart
Receive PIRS News and Ratings via Email

Sign-up to receive the latest news and ratings for Pieris Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.


Pieris Pharmaceuticals logo

About Pieris Pharmaceuticals

Pieris Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, discovers and develops anticalin protein-based drugs in the United States. The company develops anticalin proteins that are low molecular-weight therapeutic proteins derived from lipocalins, which are naturally occurring low-molecular weight human proteins found in human blood plasma and other bodily fluids. Its lead respiratory Anticalin-based drug candidate includes PRS-060/AZD1402, a drug candidate that is in Phase II clinical trial targeting IL-4Ra for the treatment of asthma and other inflammatory diseases; and lead immune-oncology program comprises Cinrebafusp alfa, a 4-1BB/ HER2 bispecific for the treatment of HER2-expressing solid tumors. The company also develops PRS-344, a bispecific anticalin-antibody fusion protein targeting 4-1BB and PD-L1 for immuno-oncology diseases; and PRS-352, a preclinical-stage program addressing undisclosed targets for immuno-oncology diseases. It has a license and collaboration agreement with Les Laboratoires Servier and Institut de Recherches Internationales Servier, AstraZeneca AB, and Seagen Inc.; and license agreements with Technical University of Munich, Enumeral Biomedical Holdings, Inc., and Sichuan Kelun-Biotech Biopharmaceutical Co. Ltd. The company also has a clinical trial collaboration and supply agreement with Eli Lilly and Company. Pieris Pharmaceuticals, Inc. was incorporated in 2000 and is headquartered in Boston, Massachusetts.

Headlines

See More Headlines

Industry, Sector and Symbol

Sales & Book Value

Profitability

Debt

Price-To-Earnings

Miscellaneous


MarketRank

Overall MarketRank

1.39 out of 5 stars

Medical Sector

742nd out of 2,099 stocks

Pharmaceutical Preparations Industry

368th out of 831 stocks

Analyst Opinion: 3.5Community Rank: 2.6Dividend Strength: 0.0Insider Behavior: 0.8Valuation: 0.0 5 -4 -3 -2 -1 -
speech bubbles
speech bubbles











Pieris Pharmaceuticals (NASDAQ:PIRS) Frequently Asked Questions

Is Pieris Pharmaceuticals a buy right now?

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Pieris Pharmaceuticals in the last twelve months. There are currently 2 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" Pieris Pharmaceuticals stock.
View analyst ratings for Pieris Pharmaceuticals
or view top-rated stocks.

What stocks does MarketBeat like better than Pieris Pharmaceuticals?

Wall Street analysts have given Pieris Pharmaceuticals a "Buy" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Pieris Pharmaceuticals wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

Are investors shorting Pieris Pharmaceuticals?

Pieris Pharmaceuticals saw a increase in short interest in the month of May. As of May 28th, there was short interest totaling 7,050,000 shares, an increase of 173.3% from the May 13th total of 2,580,000 shares. Based on an average daily trading volume, of 8,990,000 shares, the days-to-cover ratio is currently 0.8 days. Approximately 13.5% of the shares of the company are short sold.
View Pieris Pharmaceuticals' Short Interest
.

When is Pieris Pharmaceuticals' next earnings date?

Pieris Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Monday, August 9th 2021.
View our earnings forecast for Pieris Pharmaceuticals
.

How were Pieris Pharmaceuticals' earnings last quarter?

Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS) issued its quarterly earnings data on Monday, May, 17th. The biotechnology company reported ($0.07) earnings per share for the quarter, beating analysts' consensus estimates of ($0.17) by $0.10. The biotechnology company had revenue of $15.63 million for the quarter, compared to the consensus estimate of $6.47 million. Pieris Pharmaceuticals had a negative net margin of 119.28% and a negative trailing twelve-month return on equity of 94.73%.
View Pieris Pharmaceuticals' earnings history
.

How has Pieris Pharmaceuticals' stock price been impacted by Coronavirus?

Pieris Pharmaceuticals' stock was trading at $2.23 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization (WHO). Since then, PIRS stock has increased by 61.9% and is now trading at $3.61.
View which stocks have been most impacted by COVID-19
.

What price target have analysts set for PIRS?

2 brokerages have issued 1 year target prices for Pieris Pharmaceuticals' shares. Their forecasts range from $9.00 to $9.00. On average, they expect Pieris Pharmaceuticals' share price to reach $9.00 in the next year. This suggests a possible upside of 149.3% from the stock's current price.
View analysts' price targets for Pieris Pharmaceuticals
or view top-rated stocks among Wall Street analysts.

Who are Pieris Pharmaceuticals' key executives?

Pieris Pharmaceuticals' management team includes the following people:
  • Mr. Stephen S. Yoder, CEO, Pres & Director (Age 45, Pay $730.13k)
  • Mr. Thomas Bures, VP of Fin. (Age 46, Pay $360.51k)
  • Dr. Hitto Kaufmann Ph.D., Sr. VP & Chief Scientific Officer (Age 50, Pay $458.68k)
  • Mr. Ahmed S. Mousa, Sr. VP of Corp. Operations, Gen. Counsel & Corp. Sec.
  • Maria Kelman, Director of Investor Relations
  • Mr. Frank Vollmering, VP of HR
  • Dr. Christine Rothe, Head of Discovery & Alliance Management and VP
  • Dr. Shane Olwill, Sr. VP & Head of Translational Science
  • Mr. Eckhard Niemeier, Sr. VP & Head of Bus. Devel.
  • Mr. Prompong Chaikul, Chief Supply Chain Officer (Age 34)

Who are some of Pieris Pharmaceuticals' key competitors?

What other stocks do shareholders of Pieris Pharmaceuticals own?

What is Pieris Pharmaceuticals' stock symbol?

Pieris Pharmaceuticals trades on the NASDAQ under the ticker symbol "PIRS."

Who are Pieris Pharmaceuticals' major shareholders?

Pieris Pharmaceuticals' stock is owned by a number of retail and institutional investors. Top institutional investors include BlackRock Inc. (5.81%), Renaissance Technologies LLC (2.10%), Tekla Capital Management LLC (1.62%), Morgan Stanley (1.29%), Assenagon Asset Management S.A. (1.36%) and Acadian Asset Management LLC (1.27%). Company insiders that own Pieris Pharmaceuticals stock include Aquilo Capital Management, Llc and Bvf Partners L P/Il.
View institutional ownership trends for Pieris Pharmaceuticals
.

Which institutional investors are selling Pieris Pharmaceuticals stock?

PIRS stock was sold by a variety of institutional investors in the last quarter, including Woodline Partners LP, Omega Fund Management LLC, Tekla Capital Management LLC, Renaissance Technologies LLC, Acadian Asset Management LLC, Goldman Sachs Group Inc., AQR Capital Management LLC, and Morgan Stanley.
View insider buying and selling activity for Pieris Pharmaceuticals
or view top insider-selling stocks.

Which institutional investors are buying Pieris Pharmaceuticals stock?

PIRS stock was purchased by a variety of institutional investors in the last quarter, including Cerity Partners LLC, Assenagon Asset Management S.A., Sphera Funds Management LTD., GSA Capital Partners LLP, Silverarc Capital Management LLC, BlackRock Inc., Dimensional Fund Advisors LP, and D. E. Shaw & Co. Inc..
View insider buying and selling activity for Pieris Pharmaceuticals
or or view top insider-buying stocks.

How do I buy shares of Pieris Pharmaceuticals?

Shares of PIRS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Pieris Pharmaceuticals' stock price today?

One share of PIRS stock can currently be purchased for approximately $3.61.

How much money does Pieris Pharmaceuticals make?

Pieris Pharmaceuticals has a market capitalization of $228.51 million and generates $29.32 million in revenue each year. The biotechnology company earns $-37,230,000.00 in net income (profit) each year or ($0.68) on an earnings per share basis.

How many employees does Pieris Pharmaceuticals have?

Pieris Pharmaceuticals employs 111 workers across the globe.

What is Pieris Pharmaceuticals' official website?

The official website for Pieris Pharmaceuticals is www.pieris.com.

Where are Pieris Pharmaceuticals' headquarters?

Pieris Pharmaceuticals is headquartered at 255 State Street 9th Floor, Boston MA, 02109.

How can I contact Pieris Pharmaceuticals?

Pieris Pharmaceuticals' mailing address is 255 State Street 9th Floor, Boston MA, 02109. The biotechnology company can be reached via phone at 857-246-8998 or via email at [email protected]


This page was last updated on 6/14/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.